pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca clinical programs — 79 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
AstraZeneca projects
79 ClinicalTrials.gov programs sponsored by AstraZeneca.
AstraZeneca has 79 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AZD0292, Placebo for AZD0292
AstraZeneca AB
Bronchiectasis with chronic pseudomonas aeruginosa colonization
1 trial -
AZD0486, AZD0486
AstraZeneca AB
Relapsed or Refractory Non-Hodgkin Lymphoma
1 trial -
AZD1163 Placebo, AZD1163
AstraZeneca AB
Rheumatoid arthritis
1 trial -
AZD2962, AZD2962
AstraZeneca AB
Myelodysplastic syndromes, Dysplastic chronic myelomonocytic leukaemia
1 trial -
AZD3632, AZD3632
AstraZeneca AB
Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes with HOX overexpression genotypes
1 trial -
AZD4360
AstraZeneca AB
Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
1 trial -
AZD4512
AstraZeneca AB
B-cell acute lymphoblastic leukemia (B-ALL)
1 trial -
AZD4512
AstraZeneca AB
Non-Hodgkin lymphoma (NHL)
1 trial -
AZD6738, Ceralasertib
AstraZeneca AB
Advanced Cancer Whose Tumours Contain Molecular Alterations
1 trial -
AZD7789
AstraZeneca AB
Advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma, Advanced or Metastatic Non-small Cell Lung Carcinoma, Advanced or Metastatic Solid Tumors
1 trial -
AZD7798 Placebo, AZD7798
AstraZeneca AB
Crohn's Disease
1 trial -
AZD9750, Saruparib
AstraZeneca AB
Metastatic Prostate Cancer
1 trial -
AZD9793
AstraZeneca AB
Hepatocellular Carcinoma
1 trial -
CLARITY-PT01
AstraZeneca AB
Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
1 trial -
CYCAD-1(D8470C00001)
AstraZeneca AB
Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)
1 trial -
D361FC00001
AstraZeneca AB
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
1 trial -
D4190C00022
AstraZeneca AB
Hepatocellular Carcinoma
1 trial -
D419EC00001
AstraZeneca AB
Advanced Solid Tumors
1 trial -
D4880C00003
AstraZeneca AB
unresectable pleural or peritoneal malignant mesothelioma
1 trial -
D5162C00048
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D516AC00003
AstraZeneca AB
Unresectable Non-small Cell Lung Cancer
1 trial -
D5336C00001
AstraZeneca AB
Triple Negative Breast Cancer
1 trial -
D533AC00001
AstraZeneca AB
Unresectable or Advanced Melanoma
1 trial -
D6132C00001
AstraZeneca AB
First-line patients with extensive disease small-cell lung cancer (SCLC)
1 trial -
D6186C00001
AstraZeneca AB
Advanced Non-Small Cell Lung Cancer
1 trial -
D6187C00001
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D6405C00002
AstraZeneca AB
Chronic Kidney Disease and Albuminuria
1 trial -
D6830C00003
AstraZeneca AB
Asthma in adults who remain uncontrolled despite medium to high dose ICS plus LABA, and who are at risk of exacerbations.
1 trial -
D6972C00006
AstraZeneca AB
Chronic kidney disease (CKD) and hypertension.
1 trial -
D702KC00001
AstraZeneca AB
metastatic non-small cell lung cancer (NSCLC)
1 trial -
D7080C00001
AstraZeneca AB
Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma
1 trial -
D7230C00001
AstraZeneca AB
Multiple Myeloma
1 trial -
D7260C00001
AstraZeneca AB
Participants living with Obesity or Overweight with at least 1 comorbidity
1 trial -
D7261C00001
AstraZeneca AB
Type 2 Diabetes Mellitus
1 trial -
D7405C00001 (SYRUS)
AstraZeneca AB
B-Cell Acute Lymphoblastic Leukaemia
1 trial -
D7407C00001
AstraZeneca AB
Mantle Cell Lymphoma, Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
1 trial -
D7552C00001
AstraZeneca AB
Moderate-to-Severe Uncontrolled Asthma
1 trial -
D7830C00004
AstraZeneca AB
Non-cirrhotic non-alcoholic steatohepatitis with fibrosis
1 trial -
D7860C00006
AstraZeneca AB
Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
D7986C00001
AstraZeneca AB
Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
1 trial -
D798KC00001
AstraZeneca AB
Solid Tumors, SQ, NSQ NSCLC
1 trial -
D798MC00002
AstraZeneca AB
Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).
1 trial -
D8210C00003
AstraZeneca AB
Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
1 trial -
D8210C00005
AstraZeneca AB
Asthma
1 trial -
D8220C00036
AstraZeneca AB
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
1 trial -
D822GC00001
AstraZeneca AB
Treatment Naïve Mantle Cell Lymphoma
1 trial -
D8410C00001
AstraZeneca AB
Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, Module 4: advanced,unresectable and HER2+ metastatic solid tumours; NSCLC, HER2 activating mutation, Module 5: advanced,unresectable or metastatic solid tumours in breast, endometrial, ovarian and prostate cancer, Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, IDH-mutant recurrent glioma, breast cancer (without BM), Module 2: IDH-mutant glioma
1 trial -
D8460C00004
AstraZeneca AB
Investigating obesity or overweight condition correlated to many co-morbidities
1 trial
Frequently asked questions
How many clinical projects does AstraZeneca have?
79 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.